華海藥業(600521.SH)擬使用部分募集資金向子公司華海建誠、華海生物增資
格隆匯 11 月 17日丨華海藥業(600521.SH)公佈,公司於2020年11月17日召開第七屆董事會第十一次臨時會議、第七屆監事會第十次臨時會議審議通過了《關於使用部分募集資金向全資子公司增資的議案》,同意以部分公開發行可轉換公司債券的募集資金對全資子公司浙江華海建誠藥業有限公司(“華海建誠”)、浙江華海生物科技有限公司(“華海生物”)進行增資。
根據《浙江華海藥業股份有限公司公開發行可轉換公司債券募集説明書》中對於募集資金的投資項目實施計劃,公司“年產20噸培哚普利、50噸雷米普利等16個原料藥項目”募投項目的實施主體為公司全資子公司華海建誠,“生物園區製藥及研發中心項目”募投項目的實施主體為公司全資子公司華海生物。
為加快項目建設進度,在嚴格監管的前提下縮短募集資金使用的內部審批流程,提高募集資金使用效率,2020年11月17日,經公司第七屆董事會第十一次臨時會議、第七屆監事會第十次臨時會議審議通過,同意公司使用“年產20噸培哚普利、50噸雷米普利等16個原料藥項目”的募集資金約6.74億元向全資子公司華海建誠分批增資,同意公司使用“生物園區製藥及研發中心項目”的募集資金6億元向全資子公司華海生物分批增資。
公司此次對全資子公司增資的資金來源為公開發行可轉換公司債券募集的資金。此次增資是基於公司募集資金使用計劃實施的具體需要,有利於提高募集資金使用效率,保障募投項目的順利實施,符合公司業務發展規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.